Valneva SE

Valneva Wins Brazil Approval for Chikungunya Shot

Valneva, the French biotech company, has taken a major step with Brazilian health authority approval of its Ixchiq vaccine for the prevention of chikungunya, a disease endemic in Brazil. The milestone represents a significant opportunity, opening new commercial prospects in a region heavily affected by the disease. The news could potentially support Valneva shares, as the vaccine addresses an urgent public health need.